Compare Robinhood Markets, Inc. (HOOD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs BIO-TECHNE Corp — how do they compare? Robinhood Markets, Inc. trades at $94.47 (market cap $84.98B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Robinhood Markets, Inc. is far larger — about 7.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| HOOD | TECH | |
|---|---|---|
Market Cap | $84.98B | $11.24B |
Sector | Technology | Health |
52-Week High | $152.46 | $72.29 |
52-Week Low | $65.16 | $43.31 |
Enterprise Value | $91.53B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $93.29, up 2.84% today, showing strong revenue growth with 2025 revenue reaching $4.47B and net income of $1.88B. The stock faces technical headwinds with a bearish signal overall, trading near key support at $92. Recent earnings beat expectations in Q2 2026 with EPS of $0.62 versus $0.44 expected, though the company missed in Q1. Analyst sentiment remains positive with 73% buy ratings and a $123.46 consensus price target.
HOOD presents a growth opportunity with expanding product diversification and international expansion, but faces risks from competitive pressures and regulatory hurdles. Valuation metrics remain elevated with P/E of 41.28 and P/S of 17.4, requiring continued strong execution to justify current levels. The stock's near-term direction will depend on Q3 2026 earnings performance and successful execution of UK market expansion.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
